Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Homebred beef cattle are seen at a local cattle market in Hongseong, about 170 km (106 miles) south of Seoul July 29, 2008. A rare genetic mutation may underlie some cases of mad cow disease in cattle and its discovery may help shed light on where the epidemic started, U.S. researchers reported on Friday. REUTERS/Lee Jae-Won The mutation, in an Alabama cow that tested positive in 2006 for bovine spongiform encephalopathy, or BSE, is identical to one that causes a related brain-wasting disease in humans. This suggests BSE may sometimes arise spontaneously in cattle. Jurgen Richt of Kansas State University said cattle producers must never let down their guard against BSE because cattle anywhere, at any time, can develop the disease. The finding may support a 2005 theory that the BSE epidemic in cattle could be traced to feed contaminated with cattle remains from India, the researchers report in the Public Library of Science journal PLoS Pathogens. BSE or mad cow disease swept through British dairy herds in the 1980s, forcing the destruction of millions of animals. No one ever found where it came from but most experts thought at the time it came from cattle feed that contained the remains of sheep infected with a similar disease called scrapie. Cattle were never known to develop BSE before the epidemic, but some experts have argued they may have. This report lends credence to that idea. BSE, scrapie and a human version called Creutzfeldt-Jakob disease, or CJD, are brain-destroying illnesses called transmissible spongiform encephalopathies. In some cases, animals or people that eat brain and nervous system material from victims of these diseases can develop them, too. They are passed along by misfolded infectious protein fragments called prions. A very rare disease called variant CJD has been found in people who ate infected beef products. Fatal and incurable, it has affected just 167 people so far. Most countries now ban the use of meat and other parts from mammals in food for cattle. They also ban the use of potentially infectious tissues such as brain and spinal cord in human food. "There are tendencies around the world, now that the feed-borne epidemic has gone down, to relax these rules and regulations," Richt said in a telephone interview. "So if we have these genetic cases popping up here and there and we don't have our mitigations in place, we will have another epidemic somewhere." He suggested breeding the gene out of cattle. "We can clean the world cattle herd of that mutation," Richt said. CJD is also known to pop up spontaneously in the human population. A genetic mutation causes the disease in one in a million people globally. Richt and colleagues tested the brain of the Alabama cow and found a mutation identical to the prion gene mutation that causes some cases of CJD. It is probably rare in cattle, found in fewer than one in 2,000, they said in the report, published here But the animal passed along its mutation to its heifer, which suggests it is inherited. Claim: Gene mutation underlies some mad cow disease: study.

Answer: A rare genetic mutation may underlie some cases of mad cow disease in cattle and its discovery may help shed light on where the epidemic started, U.S. researchers reported on Friday.

Question: Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don't cover the cost of the new genetic test for breast cancer. The test manufacturer CEO's speculation that insurance companies will eventually cover the test because it's easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman's lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman's decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this testunlike Decode's chief executive, who is also interviewed, mainly promoting his company's product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman's risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women's risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers

Answer: "The focus of the story is a newly available genetic test to assess a woman's risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO's speculation that insurance companies will eventually cover the test because it's easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."

Question: Paragraph: Earlier on Saturday, Jakarta's governor said the city will close all schools for at least two weeks to curb the spread of coronavirus, as the first cases were also reported in other parts of the archipelago. Indonesia, the world's fourth most populous country, reported on Saturday 27 more coronavirus cases, bringing the total confirmed infections to 96 and deaths to five. Sumadi's family had given approval for the announcement after the minister had been on "the front line and a very important part of containing the impact of COVID-19", Pratikno, who is state secretary in charge of administrative support for the office of president, told a news conference. The condition of Sumadi, 63, who had attended a cabinet meeting on Wednesday, was showing an improvement, said Albertus Budi Sulistya, deputy head of the Gatot Soebroto Hospital. "He was initially being treated for other illnesses in a private hospital until he had difficulty breathing, then some medical equipment had to be brought in," said Sulistya. The health ministry had conducted some tracing of people Sumadi had recently met and "would immediately begin testing as required", said Pratikno, who uses one name. The transport minister had sat in a room with number of ministers and the army head during the cabinet meeting earlier this week, which was also attended by President Joko Widodo. While most confirmed coronavirus cases have been clustered in Jakarta, cases were also reported on Saturday in cities in western and central Java, Manado on Sulawesi island and Pontianak on Borneo island. "We must massively, in an integrated way and without panic, search and find and isolate positive cases," health ministry official Achmad Yurianto told a news briefing. Doni Monardo, who leads Indonesia's task force on coronavirus, said testing will be increased and struggling medical staff will be assisted by medical students and volunteers. As he announced school closures, Jakarta Governor Anies Baswedan said cases had been detected in many parts of the city of 10 million people. "What must be done right now is to reduce interactions between residents," Baswedan said, urging people to stay at home and not travel unless necessary. Indonesia confirmed its first cases of the virus only last week while some countries in the region had reported scores of cases far earlier, raising concerns among medical experts about infections either not being reported or going undetected. The central government has faced criticism for withholding information regarding the spread of the virus. Claim: Indonesia transport minister confirmed to have coronavirus as cases climb.

Answer:
Indonesian Transport Minister Budi Karya Sumadi has been hospitalized in Jakarta after he contracted coronavirus, a government official said on Saturday, the most high-profile case so far to be confirmed in the Southeast Asian country.